Michelle K Wilson

发表

Research Biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions and preferences.

A. Oza, S. Lheureux, Lisa I. Wang, 2021, American journal of obstetrics and gynecology.

Outcomes and endpoints in cancer trials: bridging the divide.

Katherine Karakasis, Deborah Collyar, Ian F Tannock, 2015, The Lancet. Oncology.

Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

Katherine Karakasis, A. Oza, Michelle K Wilson, 2015, The Lancet. Oncology.

A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

A. Oza, M. Friedlander, F. Joly, 2018, The oncologist.

Non-target progression--the fine line between objectivity and subjectivity.

A. Oza, S. Lheureux, Michelle K Wilson, 2014, European journal of cancer.

Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

A. Oza, Lisa I. Wang, Michelle K Wilson, 2014, Cancer.

International Gynecologic Cancer Society (IGCS) 2018: Meeting report.

Michelle K Wilson, L. Duska, D. Suh, 2019, Gynecologic oncology.

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

B. Monk, M. Morgan, D. Provencher, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

Michelle K Wilson, A. Mweempwa, M. Wilson, 2019, Cancer drug resistance.

Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care.

Michelle K Wilson, M. Findlay, S. Deva, 2017, The New Zealand medical journal.

Recent and current Phase II clinical trials in endometrial cancer: review of the state of art

H. Mackay, S. Lheureux, Michelle K Wilson, 2014, Expert opinion on investigational drugs.

Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up.

A. Shelling, H. Mackay, A. Oza, 2015, Gynecologic oncology.

Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression.

A. Shelling, Michelle K Wilson, P. Cohen, 2013, Gynecologic oncology.

A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer

M. Friedlander, Michelle K Wilson, R. Mercieca-Bebber, 2018, Journal of gynecologic oncology.

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

B. Monk, A. Oza, F. Marmé, 2021, International Journal of Gynecological Cancer.

MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markers

A. Shelling, C. Blenkiron, Michelle K Wilson, 2017, Clinical Epigenetics.

Interobserver and intraobserver variability of RECIST assessment in ovarian cancer

A. Oza, D. Moses, S. Lheureux, 2022, International Journal of Gynecological Cancer.

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.

H. Mackay, A. Oza, B. Clarke, 2015, Gynecologic oncology.

Resisting RECIST—Uniformity Versus Clinical Validity

A. Oza, M. Friedlander, S. Lheureux, 2017, International Journal of Gynecologic Cancer.

MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markers

A. Shelling, C. Blenkiron, Michelle K Wilson, 2017, Clinical Epigenetics.

Neutropenic Sepsis

Michelle K Wilson, W. Thompson, R. Stephen, 2019, Textbook of Palliative Care.

Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC).

A. Oza, J. Nemunaitis, S. Lheureux, 2014 .